<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Inhalant misuse in children and adolescents
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Inhalant misuse in children and adolescents
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Inhalant misuse in children and adolescents
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Holly Perry, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology, clinical manifestations, toxic effects, and management of inhalant misuse will be reviewed here. Substances that are nasally insufflated (eg, snorted cocaine) or smoked (eg, tobacco, marijuana, cocaine, and opiates) are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">
          "Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">
          "Opioid intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, inhalant misuse is common with approximately 11 percent of high school students reporting having used inhalants in their lifetime [
         <a href="#rid1">
          1
         </a>
         ]. An estimated 2 percent of United States adolescents (ages 12 to 17) have used an inhalant in the prior year [
         <a href="#rid2">
          2
         </a>
         ]. Unlike nearly all other classes of drugs, their use is most common among younger adolescents with use peaking between seventh and ninth grade [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The incidence of inhalant misuse in children 12 to 18 years old has fluctuated over the past 25 years. Incidence of use tripled between 1983 and 1993 [
         <a href="#rid4">
          4
         </a>
         ], peaking in 1995, and then showed a steady decline until 2002. The incidence stayed relatively unchanged but then decreased significantly starting in 2010 to 2013, coinciding with the phase-out of refrigerants that contain hydrochlorofluorocarbons by the United States Environmental Protection Agency [
         <a href="#rid3">
          3,5,6
         </a>
         ]. In the past, Native American children and those residing in rural areas were at higher risk for inhalant misuse [
         <a href="#rid7">
          7-11
         </a>
         ]. However, rates of misuse have fallen steadily in these groups and are now at levels comparable to the general population [
         <a href="#rid2">
          2
         </a>
         ]. Education on prevention and treatment is thought to be responsible for this trend [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p>
         Similar to national survey data, adolescent exposures reported to United States poison control centers have declined from 73 cases per million in 1993 to 33, 26, and 5 cases per million in 2003, 2010, and 2021, respectively [
         <a href="#rid6">
          6,10
         </a>
         ]. Among all age groups, there were 257 deaths out of 25,022 exposures between 2001 and 2021 [
         <a href="#rid6">
          6
         </a>
         ]. Males comprised 73 percent of all cases reported to poison control centers. In the United Kingdom, deaths due to volatile substance misuse peaked in the early 1990s and subsequently have declined after education campaigns and laws prohibiting cigarette lighter refills went into effect [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Since 2000, recreational
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) use has increased [
         <a href="#rid15">
          15
         </a>
         ]. In the United States, lifetime prevalence of N
         <sub>
          2
         </sub>
         O use in individuals 12 years and older is between 4 and 5 percent [
         <a href="#rid16">
          16,17
         </a>
         ]. A 2020 survey of 16 to 24 year olds in England and Wales found that nine percent had used N
         <sub>
          2
         </sub>
         O in the prior year, which was second only to cannabis [
         <a href="#rid18">
          18
         </a>
         ]. The terms "chroming" and "Whiptok" on social media refer to its misuse [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         Numerous studies have demonstrated significant mental health and behavioral comorbidities among patients who misuse inhalants. They are more likely to have an episode of major depression [
         <a href="#rid20">
          20,21
         </a>
         ], suicidality [
         <a href="#rid22">
          22
         </a>
         ], conduct disorder [
         <a href="#rid20">
          20
         </a>
         ], and are at an increased risk for future substance use disorders [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Volatile hydrocarbons and
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         have a similar mechanism of action. Like ethanol and other inhalational anesthetic agents, they are highly lipid soluble. They are rapidly absorbed across the pulmonary bed into the bloodstream and are distributed throughout the body [
         <a href="#rid24">
          24
         </a>
         ]. Neurons, which have high lipid content, are particularly susceptible to the solvent properties of these compounds [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         These inhalants act as central nervous system (CNS) depressants. CNS depression is thought to be mediated by alteration of neuronal membrane function at glutamate or gamma amino butyric acid receptors [
         <a href="#rid27">
          27-29
         </a>
         ].
        </p>
        <p>
         These inhalants produce an effect within seconds that typically lasts 15 to 30 minutes. There have been rare cases of prolonged symptoms when large quantities have been inhaled [
         <a href="#rid30">
          30
         </a>
         ]. Initial euphoria is followed by lethargy. Judgment and coordination are impaired [
         <a href="#rid31">
          31
         </a>
         ]. Intoxication is maintained through repeated use. Symptoms of tolerance to the effects of inhalants and physiologic withdrawal have been described [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) interferes with
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         , folate, and methionine synthesis and metabolism. Vitamin B12 is an essential cofactor for methionine synthase. N
         <sub>
          2
         </sub>
         O converts vitamin B12 from the active monovalent form to the inactive bivalent form, thereby causing an irreversible inhibition of methionine synthase. Methionine synthase is a ubiquitous cytosolic enzyme that plays a crucial role in the generation of methyl groups for the synthesis of DNA, RNA, tetrahydrofolate, methionine, and myelin, among other products. Inhibition of methionine synthase, which regenerates methionine from homocysteine, can increase homocysteine plasma concentrations [
         <a href="#rid33">
          33
         </a>
         ]. N
         <sub>
          2
         </sub>
         O can precipitate a functional vitamin B12 deficiency when used on a chronic basis or acutely in patients with marginal stores of vitamin B12 such as the elderly or malnourished [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Nitrites produce their pleasurable effects by intense vasodilation which produces a sensation of heat and warmth. Absorption is rapid across the pulmonary bed leading to onset of hypotension and reflex tachycardia within seconds of inhalation. Effects are brief, lasting less than five minutes. Nitrites are also used to enhance sexual pleasure by prolonging penile erection and promoting anal sphincter relaxation.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          TECHNIQUES (SNIFFING, HUFFING, OR BAGGING)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States, frequently misused inhalants include volatile substances (eg, glue, shoe polish, gasoline, paint thinners, lighter fluid, correction fluids, felt-tip markers), aerosols (eg, spray paint, computer and electronic duster sprays, deodorant and hair spray), gases (eg,
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         /"whippets", butane, propane), and nitrites ("poppers," room odorizers/"rush") [
         <a href="#rid2">
          2,10
         </a>
         ]. Each of these substances may contain more than one toxic compound  (
         <a class="graphic graphic_table graphicRef75970" href="/z/d/graphic/75970.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Inhalants may be sniffed directly from a container or sprayed directly on to a heated surface to enhance vaporization ("sniffing") [
         <a href="#rid35">
          35
         </a>
         ]. Volatile liquid substances also may be inhaled from a saturated cloth that is held under the nose or near the mouth ("huffing"), or from a bag that is placed over the mouth, nose, or head ("bagging"). The risk of asphyxia is increased with bagging because the partial pressure of hydrocarbon displaces oxygen in the alveoli. The possibility of a suicide attempt should be considered in an individual who "bags" inhalants, particularly when the bag is placed over the head [
         <a href="#rid36">
          36
         </a>
         ]. The concentration of the inhaled substance increases from sniffing, to huffing, to bagging.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         is misused most commonly as "whippets". These are small, cylindrical metal bulbs with a pierceable end that contains compressed nitrous oxide, which are meant for use as a propellant for whipped cream makers. When misused, the end is pierced with a "cracker" and the escaping gas is captured in a balloon and then inhaled. Nitrous oxide can also be sniffed from whipped cream canisters.
        </p>
        <p>
         The desired effects of inhalant use include euphoria, lightheadedness, and a general state of intoxication similar to that produced by alcohol or marijuana. The effects usually last for only 15 to 30 minutes, but can be sustained by continuous or repeated use [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          RECOGNITION OF INHALANT MISUSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhalant misuse frequently goes undetected. Clues to inhalant misuse include chemical odors on the breath, skin, or clothes, and empty solvent containers or bags, rags, or gauze in the child's possession or trash [
         <a href="#rid36">
          36
         </a>
         ]. "Glue-sniffer's rash" is an eczematoid dermatitis with erythema, inflammatory changes, and pruritus that occurs in the perioral area and extends to the midface. It is caused by the drying effects of hydrocarbons [
         <a href="#rid38">
          38
         </a>
         ]. Symptoms and signs of inhalant use are listed in the table  (
         <a class="graphic graphic_table graphicRef62589" href="/z/d/graphic/62589.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          TOXICITY AND CLINICAL FINDINGS BY AGENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the vast majority of children who misuse volatile inhalant substances do not seek or require medical attention, inhalant intoxication is potentially life-threatening. Death may result from asphyxia, suffocation, choking on vomitus, careless or dangerous behavior in potentially dangerous settings, and sudden sniffing death [
         <a href="#rid39">
          39
         </a>
         ] seen with hydrocarbon use, especially halogenated hydrocarbons.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Hydrocarbons
         </span>
         <span class="headingEndMark">
          —
         </span>
         Household products that are recreationally inhaled typically contain a mixture of hydrocarbons. They are categorized by structure: aliphatic, aromatic, and halogenated. (See
         <a class="medical medical_review" href="/z/d/html/6489.html" rel="external">
          "Acute hydrocarbon exposure: Clinical toxicity, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Aliphatic compounds are straight-chain compounds and include butane, propane, kerosene, and mineral seal oil. Gasoline is a mixture of aliphatic hydrocarbons that also may contain other substances, such as xylene, toluene, benzene, naphthalene, or lead [
         <a href="#rid24">
          24,40
         </a>
         ].
        </p>
        <p>
         Aromatic hydrocarbons are cyclic compounds containing a benzene ring and are used as industrial solvents; benzene, toluene, and xylene are encountered most commonly. Toluene is found in a large number of household products including glues, adhesives, acrylic paints, paint thinners, and automotive products [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Halogenated hydrocarbons include fluorinated hydrocarbons (freons and propellants such as 1,2-difluoroethane) and chlorinated hydrocarbons (carbon tetrachloride, trichloroethylene, trichloroethane). They are used as solvents, degreasers, and spot removers, and in the dry cleaning industry. Freons are widely used as refrigerants, propellants, and in fire extinguishers [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
         The most important toxicities are cardiac and neurological, although hydrocarbons are toxic to essentially all body systems. Certain agents are more closely associated with a particular toxicity.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          CNS effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute CNS effects include slurred speech, ataxia, disorientation, headache, hallucinations, agitation, violent behavior, and seizures [
         <a href="#rid4">
          4,44-47
         </a>
         ]. Generalized CNS depression may involve the respiratory centers of the brain, rarely causing respiratory arrest and death [
         <a href="#rid48">
          48
         </a>
         ]. Toluene intoxication can cause temporary or progressive cerebellar dysfunction and cranial neuropathies [
         <a href="#rid4">
          4,32
         </a>
         ].
        </p>
        <p>
         The long-term CNS effects are equally worrisome and include neurocognitive impairment, cerebellar dysfunction, and peripheral neuropathy [
         <a href="#rid36">
          36,47,49
         </a>
         ]. The neurologic findings may be related to loss of brain mass or abnormal perfusion. Computed tomography (CT) and magnetic resonance imaging (MRI) of inhalant users demonstrates loss of brain mass and degeneration of white matter (also called "toxic leukoencephalopathy"), respectively [
         <a href="#rid50">
          50-53
         </a>
         ]. Single photon emission computed tomography (SPECT) in long-term inhalant users demonstrates abnormal perfusion [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Chronic inhalation of gasoline vapors can lead to persistent peripheral neuropathy and myopathy with myoglobinuria and creatine kinase elevation [
         <a href="#rid55">
          55-58
         </a>
         ]. In addition, Parkinsonism can be caused by octane-enhancing additives [
         <a href="#rid59">
          59
         </a>
         ], and lead poisoning with encephalopathy may occur if lead-containing gasoline is inhaled [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6491.html" rel="external">
          "Childhood lead poisoning: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Cardiovascular effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arrhythmias, myocarditis, or myocardial infarction may rarely occur with acute or chronic use [
         <a href="#rid7">
          7,47,61
         </a>
         ]. Chronic heavy use of toluene has been reported to result in a statistically significant increase in QT dispersal, a marker for sudden death in a variety of clinical conditions [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         "Sudden sniffing death" where a patient has cardiovascular collapse associated with inhalation of volatile compound has been reported with all classes of hydrocarbon, but is most commonly seen in children who inhale halogenated hydrocarbons [
         <a href="#rid39">
          39,47,63
         </a>
         ]. Although a rare event, it is unpredictable and can occur in first time users. Commonly, it follows exertion or masturbation, both of which lead to increased catecholamine release [
         <a href="#rid39">
          39,64
         </a>
         ]. It is thought to be due to sensitization of the myocardium to catecholamines that is possibly accentuated by hypoxia associated with inhalant misuse [
         <a href="#rid32">
          32,38,39,48
         </a>
         ]. The cellular basis of this cardiac "sensitization" is uncertain but may relate to inhibition of sodium, calcium, and potassium channels, which results in an increase in QT duration and dispersion, and thus, susceptibility to catecholamine-induced delayed after-depolarizations and ventricular dysrhythmias [
         <a href="#rid47">
          47,65
         </a>
         ]. In addition, sensitization of the myocardium to catecholamines may be explained by slowing of electrical conduction through membrane gap junctions due to dephosphorylation of connexin-43 by a combination of
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         and hydrocarbons [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Other effects
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary effects
         </strong>
         – Hypoxia may result from displacement of oxygen in the alveoli, particularly with butane, isobutane, propane, and
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ], or suffocation when the patient huffs using a plastic bag. Pneumonitis with surfactant dysfunction, bronchospasm, or noncardiogenic or hemorrhagic pulmonary edema may occur [
         <a href="#rid38">
          38,41,61,67
         </a>
         ]. Exposure to fluorocarbon may cause a reactive airway syndrome similar to asthma [
         <a href="#rid68">
          68
         </a>
         ]. Pneumothorax may occur if gas is inhaled directly from a pressurized tank [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6340.html" rel="external">
          "Spontaneous pneumothorax in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal effects
         </strong>
         – The gastrointestinal effects of inhalant use include nausea, vomiting, and abdominal cramps [
         <a href="#rid44">
          44,61
         </a>
         ]. Anorexia and loss of weight may occur with chronic use [
         <a href="#rid36">
          36
         </a>
         ]. Chlorinated solvents such as trichloroethylene and 1,1,1-trichloroethane are hepatotoxic [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Renal effects
         </strong>
         – Volatile substance use may cause metabolic acidosis, urinary calculi, and glomerulonephritis [
         <a href="#rid22">
          22,29,44,70
         </a>
         ]. Toluene, in particular, causes metabolic acidosis with profound potassium and phosphate wasting [
         <a href="#rid47">
          47,71,72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2341.html" rel="external">
          "Causes of hypokalemia in adults", section on 'Nonreabsorbable anions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2292.html" rel="external">
          "The delta anion gap/delta HCO3 ratio in patients with a high anion gap metabolic acidosis", section on 'D-lactic acidosis and toluene inhalation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic effects
         </strong>
         – Inhalant misuse, particularly chronic exposure to benzene, may cause aplastic anemia and malignancy (eg, leukemia, lymphoma, multiple myeloma) [
         <a href="#rid36">
          36,69,73-75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4493.html" rel="external">
          "Acute myeloid leukemia: Pathogenesis", section on 'Chemical exposure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Inhalation of methylene chloride (dichloromethane), which is metabolized to carbon monoxide, can result in a clinically important carbon monoxide exposure with elevated carboxyhemoglobin levels [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/322.html" rel="external">
          "Carbon monoxide poisoning", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermatologic effects
         </strong>
         – "Glue-sniffer's rash" is an eczematoid dermatitis with erythema, inflammatory changes, and pruritus that occurs in the perioral area and extends to the midface. It is caused by the drying effects of hydrocarbons [
         <a href="#rid38">
          38,47
         </a>
         ]. Burns may occur when a flammable inhalant ignites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Musculoskeletal effects
         </strong>
         – Heavy toluene misuse is associated with generalized muscular weakness (often to the point of quadriparesis) and is typically accompanied by metabolic acidosis, profound hypokalemia, hypophosphatemia, rhabdomyolysis, and elevated creatine kinase. These metabolic abnormalities are caused primarily by the conversion of toluene to hippuric acid, with the subsequent rapid excretion of hippurate in the urine [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2292.html" rel="external">
          "The delta anion gap/delta HCO3 ratio in patients with a high anion gap metabolic acidosis", section on 'D-lactic acidosis and toluene inhalation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy and postnatal effects
         </strong>
         – Inhalant use during pregnancy may increase the risk of spontaneous abortion, premature delivery, or fetal malformation [
         <a href="#rid78">
          78-81
         </a>
         ]. Toluene, in particular, is associated with oral clefts, micrognathia, microcephaly, growth deficiency, and developmental delay [
         <a href="#rid82">
          82
         </a>
         ]. Infants born to mothers who used inhalants during pregnancy may have symptoms of withdrawal [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Miscellaneous
         </strong>
         – Trauma can result from falls, drowning, or motor vehicle accidents during the period of intoxication [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Nitrous oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          Nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) is used as a propellant in canisters of whipped cream, as a power booster in automobiles and motorcycles, and as a sedative/amnestic agent for painful medical and dental procedures. It usually is inhaled from a balloon [
         <a href="#rid31">
          31
         </a>
         ]. Neurologic, hematologic, and reproductive toxicity may result from exposure to N
         <sub>
          2
         </sub>
         O.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic effects
         </strong>
         – Neurologic toxicity is well documented in patients who misuse N
         <sub>
          2
         </sub>
         O, and due to its effects on
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         . Neurological findings include sensorimotor polyneuropathy [
         <a href="#rid37">
          37,86-88
         </a>
         ], ataxia [
         <a href="#rid34">
          34,87,89
         </a>
         ], and psychosis [
         <a href="#rid89">
          89,90
         </a>
         ]. The clinical effects are commonly from a myelopathy involving the cervical spine similar to the subacute combined degeneration syndrome associated with pernicious anemia [
         <a href="#rid91">
          91-95
         </a>
         ]. Neurotoxicity is potentially reversible with vitamin B12 (cyanocobalamin) supplementation and abstinence from N
         <sub>
          2
         </sub>
         O [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic effects
         </strong>
         – N
         <sub>
          2
         </sub>
         O misuse or use as an anesthetic agent causes megaloblastic changes due to its interaction with
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         [
         <a href="#rid96">
          96,97
         </a>
         ]. Macrocytic anemia occurs commonly in patients who chronically misuse [
         <a href="#rid95">
          95,98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Case reports have described N
         <sub>
          2
         </sub>
         O misuse associated with venous thromboembolism (VTE), such as ischemic stroke, cerebral venous thrombosis, myocardial infarction, deep venous thrombosis (DVT), and pulmonary embolism (PE) [
         <a href="#rid99">
          99-107
         </a>
         ]. N
         <sub>
          2
         </sub>
         O inhibition of
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         and methionine synthase can result in increased plasma homocysteine concentrations, which has been associated with an increased risk of VTE in some studies. (See
         <a class="medical medical_review" href="/z/d/html/6837.html" rel="external">
          "Overview of homocysteine", section on 'Venous thromboembolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A single-center, retrospective study of patients with recreational N
         <sub>
          2
         </sub>
         O misuse (326 patients) identified 17 patients with a VTE event [
         <a href="#rid108">
          108
         </a>
         ]. The majority of events were DVT/PE but also included acute coronary syndrome, ischemic stroke, cerebral vein thrombosis, portal vein thrombosis, and femoral artery thrombosis. Most patients were young (median age 26 years, range 18 to 32, one patient was 53 years) and without VTE risk factors. In nine patients with VTE who had measured serum homocysteine concentrations, eight had elevated concentrations with a median concentration of 125 micromol/L and range of 22 to 253 micromol/L (normal homocysteine concentrations are 5 to 15 micromol/L; a concentration &gt;100 micromol/L is considered severely elevated). In 104 patients with neurologic complaints and no VTE who had measured serum homocysteine concentrations, 94 had elevated concentrations with a median concentration of 99 micromol/L and range of 3 to 314 micromol/L. In this cohort, hyperhomocysteinemia was associated with N
         <sub>
          2
         </sub>
         O misuse and may have been a contributing factor for VTE, although VTE did not occur in most patients with severe hyperhomocysteinemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reproductive effects
         </strong>
         – Given N
         <sub>
          2
         </sub>
         O effects on
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         and methionine synthase, it is plausible to assume that N
         <sub>
          2
         </sub>
         O may have reproductive health risks. Animal studies have demonstrated fetotoxicity with prolonged exposure to N
         <sub>
          2
         </sub>
         O. Human studies are difficult to interpret given the number of confounding variables [
         <a href="#rid29">
          29
         </a>
         ]. However, a study of occupationally exposed healthcare workers has demonstrated a dose-dependent correlation between N
         <sub>
          2
         </sub>
         O exposure and DNA damage [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary effects
         </strong>
         – Pneumothorax may occur if gas is inhaled directly from a pressurized tank [
         <a href="#rid36">
          36,110
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6340.html" rel="external">
          "Spontaneous pneumothorax in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Nitrites
         </span>
         <span class="headingEndMark">
          —
         </span>
         Alkyl nitrites (amyl, butyl, and isobutyl nitrites) have been misused for nearly 150 years [
         <a href="#rid111">
          111
         </a>
         ].
         <a class="drug drug_general" data-topicid="8767" href="/z/d/drug information/8767.html" rel="external">
          Amyl nitrite
         </a>
         is available by prescription for treatment of angina pectoris and as part of some commercially available kits for treatment of cyanide toxicity. It is available in a glass ampule encased in a woven absorbent covering. The ampule is broken or "popped" and the covering held close to the nose and inhaled. Butyl and isobutyl nitrites (also known as "Rush" and "Climax") are used as room deodorizers, particularly for locker rooms. They also are sold as "liquid incense." They were banned by the Anti-Drug Abuse Act of 1988, but are still available illegally, as are isopropyl and cyclohexyl nitrites [
         <a href="#rid111">
          111
         </a>
         ]. They are typically sniffed directly from the container.
        </p>
        <p>
         Inhalation of nitrite causes smooth muscle relaxation resulting in peripheral vasodilatation, flushing, and hypotension with reflex tachycardia. Dilation of cerebral blood vessels causes an increase in intracranial pressure (the "rush" reportedly experienced by users), headache, nausea, and syncope. Skin irritation, tracheobronchitis, and allergic reactions with wheezing and pruritus may occur [
         <a href="#rid112">
          112,113
         </a>
         ].
        </p>
        <p>
         Inhalation of nitrite may cause acute acquired methemoglobinemia, although this toxicity is much more common after oral ingestions [
         <a href="#rid111">
          111,114
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/7104.html" rel="external">
          "Drug-induced hemolytic anemia", section on 'Methemoglobinemia'
         </a>
         ). Patients with acute acquired methemoglobinemia are symptomatic because the acute impairment of oxygen delivery to tissues does not allow sufficient time for compensatory mechanisms. Early symptoms include headache, fatigue, dyspnea, and lethargy. At higher methemoglobin levels (eg, greater than 70 percent), respiratory depression, altered consciousness, shock, seizures, and death may occur [
         <a href="#rid24">
          24,111,115,116
         </a>
         ].
        </p>
        <p>
         In addition, nitrite vapors are highly flammable, and serious burn injuries can occur if the substance comes into contact with a candle, cigarette, or other open flame.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          ANCILLARY STUDIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with inhalant intoxication should have the following performed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid blood glucose (all patients with altered mental status)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulse oximetry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electrocardiogram and continuous cardiac monitoring for arrhythmias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine screen for drugs of abuse
        </p>
        <p>
        </p>
        <p>
         In addition, the following may be performed, especially in adolescents suspected of chronic misuse [
         <a href="#rid25">
          25,117
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count to evaluate for bone marrow suppression or macrocytic anemia (benzene,
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         misuse)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes to identify hypokalemia and metabolic acidosis (toluene misuse)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liver enzymes (AST [aspartate aminotransferase] and ALT [alanine aminotransferase]), blood urea nitrogen, and serum creatinine to detect liver or renal impairment (halogenated hydrocarbons)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          Vitamin B12
         </a>
         , homocysteine, and methylmalonic acid (
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         misuse)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine rapid dipstick and microscopic urinalysis to assess for renal tubular acidosis (chronic toluene use) or findings consistent with interstitial nephritis (halogenated hydrocarbons) (see
         <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">
          "Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Methemoglobin levels should be obtained if nitrite misuse is suspected or if clinical features of methemoglobinemia are evident (eg, very dark or chocolate brown venous blood or cyanosis that does not resolve with supplemental oxygen). (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Clinical presentation (acquired/toxic)'
         </a>
         .)
        </p>
        <p>
         A venous blood lead level is appropriate in patients in whom leaded gasoline misuse is suspected.
        </p>
        <p>
         A chest radiograph should be obtained in patients with hypoxemia, rales, or respiratory distress. Abnormalities on chest radiograph may develop as late as 24 hours after exposure in symptomatic patients [
         <a href="#rid38">
          38
         </a>
         ]. They include increased bronchovascular markings, bibasilar and perihilar infiltrates, and pneumatoceles [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         In patients with signs or symptoms of peripheral neuropathy or myelopathy, especially with a history of
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         misuse, we obtain an MRI of the spine and nerve conduction studies [
         <a href="#rid117">
          117
         </a>
         ]. In patients with chronic nitrous oxide misuse, a common MRI finding is T
         <sub>
          2
         </sub>
         hyperintensities in the posterior column of the cervical spinal cord [
         <a href="#rid95">
          95,98,118
         </a>
         ]. Nerve conduction studies commonly show axonal degeneration with or without demyelination [
         <a href="#rid92">
          92,94,95
         </a>
         ].
        </p>
        <p>
         Although exposure to some hydrocarbons may be confirmed by detection of urinary metabolites (eg, trichloroethanol after chlorinated hydrocarbon exposure, hippuric acid after toluene exposure) or directly measured in the blood (eg, toluene), these laboratory studies are not rapidly available and do not change management priorities. Thus, they are not usually performed in patients with acute inhalant intoxication.
        </p>
        <p class="headingAnchor" id="H1146562700">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhalant misuse is a clinical diagnosis based on history or circumstance (eg, patient found unresponsive with toxic inhalant or inhalant apparatus nearby) and physical findings that distinguish inhalant misuse from other substances. (See
         <a class="local">
          'Techniques (sniffing, huffing, or bagging)'
         </a>
         above and
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         Specific inhaled agents are suggested by certain clinical findings as shown in the table  (
         <a class="graphic graphic_table graphicRef68976" href="/z/d/graphic/68976.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
         The diagnosis of chronic
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         use is supported by increased serum concentrations of homocysteine and methylmalonic acid and decreased
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         <sub>
         </sub>
         (although the latter may be normal in one-third of patients with neurologic manifestations) [
         <a href="#rid95">
          95,98,117,119
         </a>
         ]. The presence of T
         <sub>
          2
         </sub>
         hyperintensities on MRI of the spinal cord and axonal degeneration on nerve conduction studies also supports the diagnosis. (See
         <a class="local">
          'Ancillary studies'
         </a>
         above.)
        </p>
        <p>
         Exposure to some hydrocarbons may be detected by urinary metabolites (eg, trichloroethanol after chlorinated hydrocarbon exposure, hippuric acid after toluene exposure) or directly measured in the blood (eg, toluene). Although not typically performed in patients with acute intoxication, such testing may be used to identify continued use during substance use disorder treatment.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhalant misuse causes a wide spectrum of physical findings. Patients with acute inhalant intoxication often have the characteristic sweet solvent odor of halogenated hydrocarbons or the "glue" odor of toluene detectable on the breath. Chronic users may also have the characteristic perioral skin rash (glue sniffer’s rash) (see
         <a class="local">
          'Other effects'
         </a>
         above). When the diagnosis is not clear based upon clinical findings, the clinician must consider other agents that can cause altered mental status and/or cardiac tachyarrhythmias as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coma with respiratory depression
         </strong>
         – All patients with coma warrant measurement of a rapid blood glucose to exclude hypoglycemia. If not clinically apparent, acute inhalant intoxication can be difficult to distinguish from the many agents that can cause lethargy and coma  (
         <a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">
          table 4
         </a>
         ). Opioids, ethanol, and sedative-hypnotics (eg, benzodiazepines or barbiturates) are key substances to consider. Opioid intoxication typically responds readily to
         <a class="drug drug_pediatric" data-topicid="12628" href="/z/d/drug information/12628.html" rel="external">
          naloxone
         </a>
         administration. Ethanol can be detected by saliva, serum, and breath samples. Sedative-hypnotic agents are not typically associated with tachycardia or tachyarrhythmias which may arise from pulmonary hypoxia and catecholamine sensitization after inhalant use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ventricular tachyarrhythmias
         </strong>
         – Many agents are associated with ventricular arrhythmias or prolongation of the QRS or QT intervals which predispose to such arrhythmias  (
         <a class="graphic graphic_table graphicRef66773" href="/z/d/graphic/66773.html" rel="external">
          table 5
         </a>
         ). Sympathomimetics such as cocaine and amphetamine and anticholinergic agents such as antihistamines, antipsychotics, and cyclic antidepressants can sometimes be distinguished from acute inhalant intoxication by the presence of characteristic toxidromes, ie, physical findings associated with poisoning by these agents  (
         <a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">
          table 6
         </a>
         ). Electrolytes should be obtained rapidly to identify hyperkalemia or hypocalcemia.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of acute inhalant intoxication is supportive. Maintenance of cardiorespiratory function and removal of the child from the source of the toxin (eg, bottle, rag or bag, or contaminated clothing) are of primary importance.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Supportive care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Supplemental 100 percent oxygen by a nonrebreather face mask is administered to treat hypoxia.
        </p>
        <p class="headingAnchor" id="H1146563053">
         <span class="h3">
          Coma with respiratory depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respiratory depression often responds transiently to tactile stimulation of the patient. However, clinicians should proceed with endotracheal intubation and mechanical ventilation if there is any doubt about the patient's ability to breathe adequately on their own or if pulmonary aspiration poses a significant risk.
        </p>
        <p class="headingAnchor" id="H1146563066">
         <span class="h3">
          Ventricular arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with ventricular arrhythmias should receive countershock treatment according to international resuscitation guidelines  (
         <a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/6311.html" rel="external">
          "Technique of defibrillation and cardioversion in children (including automated external defibrillation)"
         </a>
         .)
        </p>
        <p>
         If medication administration is necessary according to Pediatric Life Support Protocols (PALS), we suggest that patients who have ventricular arrhythmias after inhalant use receive
         <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         rather than
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         . Amiodarone has been successfully used to treat butane-induced ventricular fibrillation in one case [
         <a href="#rid120">
          120
         </a>
         ]. Children who have inhaled halogenated hydrocarbons may develop ventricular arrhythmias in response to parenterally administered epinephrine or other catecholamines (eg,
         <a class="drug drug_pediatric" data-topicid="12650" href="/z/d/drug information/12650.html" rel="external">
          norepinephrine
         </a>
         ) because these treatments can theoretically precipitate or worsen arrhythmias in the irritable myocardium [
         <a href="#rid61">
          61,75
         </a>
         ].
        </p>
        <p>
         For patients who persist with ventricular arrhythmias after inhalant use despite the use of Pediatric Advanced Life Support protocols, administration of
         <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">
          esmolol
         </a>
         is an option based upon case reports of reversal of arrhythmias in patients poisoned with trichloroethylene [
         <a href="#rid121">
          121,122
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1146563072">
         <span class="h3">
          Hypokalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic toluene inhalation can present with hypokalemia and weakness [
         <a href="#rid123">
          123
         </a>
         ]. In one case series, parenteral potassium as well as
         <a class="drug drug_pediatric" data-topicid="12795" href="/z/d/drug information/12795.html" rel="external">
          sodium bicarbonate
         </a>
         for pH &lt;7.2 corrected serum and reversed electrolyte and muscle abnormalities within 24 to 36 hours. Patients with hypokalemia and muscle weakness caused by toluene misuse warrant careful administration of parenteral potassium while monitoring electrolytes, including calcium and phosphorus. Dextrose administration should be avoided as it can exacerbate hypokalemia. (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Intravenous therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Antidotes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific antidotes may be necessary to treat methemoglobinemia caused by nitrite exposure, lead toxicity due to inhalation of leaded gasoline, or
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O) neurotoxicity:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with methemoglobinemia who are symptomatic should be treated with high-dose oxygen and intravenous
         <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">
          methylene blue
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Management (acquired/toxic)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lead toxicity may require chelation therapy, depending on the results of lead levels obtained from whole blood. (See
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a patient with neurotoxicity from N
         <sub>
          2
         </sub>
         O misuse, we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         [
         <a href="#rid119">
          119
         </a>
         ]. A reasonable approach is to administer 1000 mcg intramuscular (IM) or deep subcutaneous (SUBQ) daily for one to two weeks, then a 1000 mcg IM/SUBQ weekly or 2000 mcg orally daily until manifestations resolve [
         <a href="#rid117">
          117
         </a>
         ]. N
         <sub>
          2
         </sub>
         O misuse causes a functional vitamin B12 deficiency, but the benefit of vitamin B12 supplementation is not well studied, and evidence is limited to case reports and case series. Some experts also treat with methionine 1 g three times days for at least four to six weeks, but evidence is limited to even fewer case series [
         <a href="#rid117">
          117,119,124-126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Psychiatric care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acutely, patients with findings of inhalant misuse should undergo screening for substance use disorder, depression, and suicidality [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7807.html" rel="external">
          "Substance use disorders: Clinical assessment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">
          "Screening for depression in adults"
         </a>
         .)
        </p>
        <p>
         Long-term management includes referral for substance use disorder treatment and a formal period of detoxification if indicated [
         <a href="#rid36">
          36
         </a>
         ]. Chronic complications of misuse may resolve if substance use is discontinued. Polydrug use and coexisting psychopathology are common occurrences, complicating substance use treatment. Residential treatment may improve outcome. Systematic data comparing different approaches to treatment are lacking [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Disposition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with significant toxicity marked by central nervous system findings (eg, coma, seizures) or cardiac arrhythmias warrant hospital admission to a unit with pediatric critical care capability.
        </p>
        <p>
         Children who receive treatment for methemoglobinemia or lead toxicity may also require admission depending on the degree of toxicity.
        </p>
        <p>
         Children who express suicidal thoughts need urgent psychiatric evaluation for possible admission to a mental health facility.
        </p>
        <p>
         Patients who are asymptomatic in the emergency department or have mild symptoms (eg, lethargy) that quickly resolve may be discharged home as long as appropriate mental health and primary care follow-up are assured.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pediatricians should maintain awareness of the clinical features and complications of inhalant misuse and promote education about the health hazards of inhalants to children, adolescents, parents, teachers, and vendors of volatile substances. Middle school and high school administrators should consider taking the following actions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review purchases of school supplies and substitute water-based products for solvent-based products whenever possible. Explain that the school is looking for ways to reduce indoor air pollution. Describing solvent-based products as inhalants or drugs may arouse the curiosity of students.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Closely monitor the use of solvent-based products and gases; in schools, such products should be checked out and in.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide information to school faculty, staff, and nurses.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Educate parents about the dangers of inhalant misuse.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review the appropriate use and consequences of misuse of solvents and gases whenever these products are used (eg, vocational programs, science, art).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Develop a plan of action to treat students who use inhalants.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11202453">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1509101732">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3959273620">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112688.html" rel="external">
          "Society guideline links: Poisoning prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of action
         </strong>
         – Volatile substances produce a rapid feeling of euphoria and inebriation because of their rapid absorption through the pulmonary vascular bed, their lipophilic properties that allow for quick distribution into the brain, and their effects on neuronal membrane function at glutamate or gamma amino butyric acid receptors. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – The most frequently used inhalants include glue, shoe polish, or toluene; gasoline or lighter fluid;
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         or "whippets"; and spray paints. Each of these substances may contain more than one toxic compound  (
         <a class="graphic graphic_table graphicRef75970" href="/z/d/graphic/75970.html" rel="external">
          table 1
         </a>
         ). Common routes of use involve sniffing, huffing, or bagging to concentrate the inhaled substance. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Techniques (sniffing, huffing, or bagging)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recognizing inhalant misuse
         </strong>
         – Inhalant misuse frequently goes undetected. Clues to inhalant misuse include chemical odors on the breath, skin, or clothes and empty solvent containers or bags, rags, or gauze in the child's possession or trash. Children may also display characteristic skin changes (eg, glue sniffer's rash)  (
         <a class="graphic graphic_table graphicRef62589" href="/z/d/graphic/62589.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Recognition of inhalant misuse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features of toxicity
         </strong>
         – Although the vast majority of children who misuse volatile inhalant substances do not seek or require medical attention, inhalant intoxication is potentially life threatening. Cardiac arrhythmias and central nervous system dysfunction (inebriation, agitation, seizures) are the most concerning acute toxic effects of volatile inhalants, especially hydrocarbons. Death may result from asphyxia, suffocation, choking on vomitus, careless or dangerous behavior in potentially dangerous settings, and sudden sniffing death seen with hydrocarbon use. Additional findings or acute and chronic toxicity vary by agent, as presented in the table  (
         <a class="graphic graphic_table graphicRef68976" href="/z/d/graphic/68976.html" rel="external">
          table 3
         </a>
         ), and include the following (see
         <a class="local">
          'Toxicity and clinical findings by agent'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Methemoglobinemia (nitrites)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lead toxicity (leaded gasoline)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polyneuropathy, myelopathy, venous thromboembolism, and megaloblastic anemia (
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Muscle weakness, hypokalemia, and metabolic acidosis (toluene)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carbon monoxide poisoning (methylene chloride)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ancillary studies
         </strong>
         – Patients with altered mental status should undergo rapid measurement of blood glucose. Pulse oximetry and an electrocardiogram should be obtained. The following can be performed as indicated: urine screen for drugs of abuse, complete blood count, serum electrolytes, blood urea nitrogen, serum creatinine, liver transaminases, urinalysis, methemoglobin level, venous blood lead level, and chest radiograph. Patients with neurologic manifestations and chronic
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         use should have serum
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         , homocysteine, and methylmalonic acid concentrations, MRI of spine, and nerve conduction studies. Exposure to some hydrocarbons (eg, toluene, trichloroethanol) may be confirmed with blood or urine metabolite assays; these laboratory studies are not rapidly available, do not change management priorities, and are not usually performed in patients with acute inhalant intoxication. (See
         <a class="local">
          'Ancillary studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Management of acute inhalant intoxication is primarily supportive (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Respiratory depression or coma
         </strong>
         – Supplemental 100 percent oxygen by a nonrebreather face mask should be administered to treat hypoxia. Clinicians should proceed with endotracheal intubation and mechanical ventilation if there is any doubt about the patient's ability to breathe adequately or if pulmonary aspiration poses a significant risk. (See
         <a class="local">
          'Coma with respiratory depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ventricular arrhythmias
         </strong>
         – Children with ventricular arrhythmias should receive synchronized cardioversion or defibrillation according to international resuscitation guidelines  (
         <a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6311.html" rel="external">
          "Technique of defibrillation and cardioversion in children (including automated external defibrillation)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In a patient with inhalant use who requires medication for ventricular arrhythmias according to Pediatric Life Support algorithms  (
         <a class="graphic graphic_algorithm graphicRef129942" href="/z/d/graphic/129942.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">
          algorithm 2
         </a>
         ), we suggest administration of
         <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">
          amiodarone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">
          lidocaine
         </a>
         rather than
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For a patient who persists with ventricular arrhythmias after inhalant use despite the use of Pediatric Advanced Life Support (PALS) protocols, administration of
         <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">
          propranolol
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">
          esmolol
         </a>
         may be beneficial. (See
         <a class="local">
          'Ventricular arrhythmias'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypokalemia and muscle weakness
         </strong>
         – Patients with these caused by toluene misuse warrant careful administration of parenteral potassium while monitoring electrolytes, including calcium and phosphorus. Dextrose administration should be avoided. (See
         <a class="local">
          'Hypokalemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Intravenous therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Methemoglobinemia
         </strong>
         – Patients with methemoglobinemia (eg, from nitrite exposure) who are symptomatic should be treated with high-dose oxygen and intravenous
         <a class="drug drug_pediatric" data-topicid="12599" href="/z/d/drug information/12599.html" rel="external">
          methylene blue
         </a>
         . (See
         <a class="local">
          'Antidotes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">
          "Methemoglobinemia", section on 'Management (acquired/toxic)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lead toxicity
         </strong>
         – Patients with lead toxicity (eg, inhalation of leaded gasoline) may require chelation therapy depending on the results of lead levels obtained from whole blood. (See
         <a class="local">
          'Antidotes'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6494.html" rel="external">
          "Childhood lead poisoning: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neurotoxicity from
         </strong>
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         <strong>
          (N
         </strong>
         <strong>
          <sub>
           2
          </sub>
         </strong>
         <strong>
          O) misuse
         </strong>
         – In a patient with neurotoxicity from N
         <sub>
          2
         </sub>
         O misuse, we suggest treatment with
         <a class="drug drug_pediatric" data-topicid="13187" href="/z/d/drug information/13187.html" rel="external">
          vitamin B12
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antidotes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Substance use disorder screening and treatment
         </strong>
         – Patients with findings of inhalation misuse should undergo screening for substance use disorder, depression, and suicidality. Long-term management includes referral for substance use disorder treatment and a formal period of detoxification, as needed. (See
         <a class="local">
          'Psychiatric care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20315929">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Erin Endom, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance - United States, 2011. MMWR Surveill Summ 2012; 61:1.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators
in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No.
PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and
Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report (Accessed on June 29, 2023).
         </li>
         <li class="breakAll">
          Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Results on Adolescent Drug Abuse: Overview of Key Findings, 2010. 2011. http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2010.pdf (Accessed on November 30, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neumark YD, Delva J, Anthony JC. The epidemiology of adolescent inhalant drug involvement. Arch Pediatr Adolesc Med 1998; 152:781.
          </a>
         </li>
         <li class="breakAll">
          SAMHSA. Behavioral health trends in the United States: Results from the 2014 national survey on drug use and health. http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf (Accessed on August 29, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogge RL, Spiller HA, Kistamgari S, et al. Inhalant misuse reported to America's Poison Centers, 2001-2021. Clin Toxicol (Phila) 2023; 61:453.
          </a>
         </li>
         <li class="breakAll">
          Osterhoudt KC, Burns Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.951.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauvais F. Comparison of drug use rates for reservation Indian, non-reservation Indian and Anglo youth. Am Indian Alsk Native Ment Health Res 1992; 5:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiller H, Lorenz DJ. Trends in volatile substance abuse. J Addict Dis 2009; 28:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsolek MR, White NC, Litovitz TL. Inhalant abuse: monitoring trends by using poison control data, 1993-2008. Pediatrics 2010; 125:906.
          </a>
         </li>
         <li class="breakAll">
          Johnston, L. D., O’Malley, P. M., Bachman, J. G., Schulenberg, J. E. &amp; Miech, R. A. (2014). Monitoring the Future national survey results on drug use, 1975–2013: Volume I, Secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan. Available at http://monitoringthefuture.org/pubs/monographs/mtf-vol1_2013.pdf (Accessed July 14, 2014)
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauvais F, Jumper-Thurman P, Burnside M. The changing patterns of drug use among American Indian students over the past 30 years. Am Indian Alsk Native Ment Health Res 2008; 15:15.
          </a>
         </li>
         <li class="breakAll">
          Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. (December 18, 2013). "American teens more cautious about using synthetic drugs." University of Michigan News Service: Ann Arbor, MI. http://www.monitoringthefuture.org (Accessed on July 20, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butland BK, Field-Smith ME, Ramsey JD, Anderson HR. Twenty-five years of volatile substance abuse mortality: a national mortality surveillance programme. Addiction 2013; 108:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Amsterdam JG, Nabben T, van den Brink W. Increasing recreational nitrous oxide use: Should we worry? A narrative review. J Psychopharmacol 2022; 36:943.
          </a>
         </li>
         <li class="breakAll">
          Key substance use and mental health indicators in the United States: results from the 2020 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFFRPDFWHTMLFiles2020/2020NSDUHFFR1PDFW102121.pdf (Accessed on July 19, 2022).
         </li>
         <li class="breakAll">
          SAMHSA 2018 National Survey on Drug Use and Health. Public use file codebook. Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality, Rockville, MD. http://samhda.s3-us-govwest-1.amazonaws.com/s3fs-public/field-uploads-protected/studies/NSDUH-2018/NSDUH-2018-datasets/NSDUH-2018-DS0001/ NSDUH-2018-DS0001-info/NSDUH-2018-DS0001-info-codebook.pdf (Accessed on October 03, 2022).
         </li>
         <li class="breakAll">
          Office for National Statistics. Drug misuse in England and Wales: year ending March 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/crimeandjustice/articles/drugmisuseinenglandandwales/yearendingmarch2020 (Accessed on October 03, 2022).
         </li>
         <li class="breakAll">
          New York Post. What is chroming? Inside lethal trend as teen dies from huffing toxic chemicals. May 23, 2023. https://nypost.com/article/what-is-chroming/ (Accessed on August 30, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard MO, Walker RD, Walker PS, et al. Inhalant use among urban American Indian youth. Addiction 1999; 94:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai JT, Hall SK, Mikulich-Gilbertson SK, Crowley TJ. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry 2004; 43:1080.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedenthal S, Vaughn MG, Jenson JM, Howard MO. Inhalant use and suicidality among incarcerated youth. Drug Alcohol Depend 2007; 90:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson EO, Schütz CG, Anthony JC, Ensminger ME. Inhalants to heroin: a prospective analysis from adolescence to adulthood. Drug Alcohol Depend 1995; 40:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHugh MJ. The abuse of volatile substances. Pediatr Clin North Am 1987; 34:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtzman TL, Otsuka KN, Wahl RA. Inhalant abuse by adolescents. J Adolesc Health 2001; 28:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chadwick O, Anderson R, Bland M, Ramsey J. Neuropsychological consequences of volatile substance abuse: a population based study of secondary school pupils. BMJ 1989; 298:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deitrich RA, Dunwiddie TV, Harris RA, Erwin VG. Mechanism of action of ethanol: initial central nervous system actions. Pharmacol Rev 1989; 41:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jevtović-Todorović V, Todorović SM, Mennerick S, et al. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med 1998; 4:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology 2008; 109:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris D, Mirza Z. Butane encephalopathy. Emerg Med J 2005; 22:676.
          </a>
         </li>
         <li class="breakAll">
          A campaign to prevent inhalant abuse. Bureau of Substance Abuse Services, Massachusetts Department of Public Health.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinwiddie SH. Abuse of inhalants: a review. Addiction 1994; 89:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myles PS, Chan MT, Kaye DM, et al. Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function. Anesthesiology 2008; 109:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller MA, Martinez V, McCarthy R, Patel MM. Nitrous oxide "whippit" abuse presenting as clinical B12 deficiency and ataxia. Am J Emerg Med 2004; 22:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henretig F. Inhalant abuse in children and adolescents. Pediatr Ann 1996; 25:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espeland K. Identifying the manifestations of inhalant abuse. Nurse Pract 1995; 20:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brust JC. Other agents. Phencyclidine, marijuana, hallucinogens, inhalants, and anticholinergics. Neurol Clin 1993; 11:555.
          </a>
         </li>
         <li class="breakAll">
          McManus B. Hydrocarbons. In: Pediatric Emergency Medicine: A Comprehensive Study Guide, Strange GR, Ahrens W, Lelyveld S, Schafermeyer R (Eds), McGraw Hill, New York 1996. p.538.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass M. Sudden sniffing death. JAMA 1970; 212:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med 2000; 38:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurbat RS, Pollack CV Jr. Facial injury and airway threat from inhalant abuse: a case report. J Emerg Med 1998; 16:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegener EE, Barraza KR, Das SK. Severe frostbite caused by Freon gas. South Med J 1991; 84:1143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerhardt RT. Acute Halon (bromochlorodifluoromethane) toxicity by accidental and recreational inhalation. Am J Emerg Med 1996; 14:675.
          </a>
         </li>
         <li class="breakAll">
          Scalzo AJ. Inhalation injuries. In: Pediatric Emergency Medicine: Concepts and Clinical Practice, Barkin RM (Ed), Mosby, St. Louis 1997. p.594.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weaver MF, Jarvis MA, Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med 1999; 159:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lolin Y. Chronic neurological toxicity associated with exposure to volatile substances. Hum Toxicol 1989; 8:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tormoehlen LM, Tekulve KJ, Nañagas KA. Hydrocarbon toxicity: A review. Clin Toxicol (Phila) 2014; 52:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shepherd RT. Mechanism of sudden death associated with volatile substance abuse. Hum Toxicol 1989; 8:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yücel M, Takagi M, Walterfang M, Lubman DI. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci Biobehav Rev 2008; 32:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornazzari L, Wilkinson DA, Kapur BM, Carlen PL. Cerebellar, cortical and functional impairment in toluene abusers. Acta Neurol Scand 1983; 67:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenberg NL, Spitz MC, Filley CM, et al. Central nervous system effects of chronic toluene abuse--clinical, brainstem evoked response and magnetic resonance imaging studies. Neurotoxicol Teratol 1988; 10:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filley CM, Heaton RK, Rosenberg NL. White matter dementia in chronic toluene abuse. Neurology 1990; 40:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Küçük NO, Kiliç EO, Ibis E, et al. Brain SPECT findings in long-term inhalant abuse. Nucl Med Commun 2000; 21:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortenberry JD. Gasoline sniffing. Am J Med 1985; 79:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gallassi R, Montagna P, Pazzaglia P, et al. Peripheral neuropathy due to gasoline sniffing - A case report. Eur Neurol 1980; 19:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovanen J, Somer H, Schroeder P. Acute myopathy associated with gasoline sniffing. Neurology 1983; 33:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maruff P, Burns CB, Tyler P, et al. Neurological and cognitive abnormalities associated with chronic petrol sniffing. Brain 1998; 121 ( Pt 10):1903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenenbein M. Leaded gasoline abuse: the role of tetraethyl lead. Hum Exp Toxicol 1997; 16:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cairney S, O' Connor N, Dingwall KM, et al. A prospective study of neurocognitive changes 15 years after chronic inhalant abuse. Addiction 2013; 108:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carder JR, Fuerst RS. Myocardial infarction after toluene inhalation. Pediatr Emerg Care 1997; 13:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alper AT, Akyol A, Hasdemir H, et al. Glue (toluene) abuse: increased QT dispersion and relation with unexplained syncope. Inhal Toxicol 2008; 20:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adgey AA, Johnston PW, McMechan S. Sudden cardiac death and substance abuse. Resuscitation 1995; 29:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poklis A. Letter: Sudden sniffing death. Can Med Assoc J 1976; 115:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson LS. Toxicologic myocardial sensitization. J Toxicol Clin Toxicol 2002; 40:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiao Z, De Jesús VR, Iravanian S, et al. A possible mechanism of halocarbon-induced cardiac sensitization arrhythmias. J Mol Cell Cardiol 2006; 41:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald RL, Fishel CE, Bush LL. Fatality due to recreational use of chlorodifluoromethane and chloropentafluoroethane. J Forensic Sci 1993; 38:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Hoz RE. Reactive airways dysfunction syndrome following exposure to a fluorocarbon. Eur Respir J 1999; 13:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marjot R, McLeod AA. Chronic non-neurological toxicity from volatile substance abuse. Hum Toxicol 1989; 8:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance--United States, 2007. MMWR Surveill Summ 2008; 57:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Streicher HZ, Gabow PA, Moss AH, et al. Syndromes of toluene sniffing in adults. Ann Intern Med 1981; 94:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taher SM, Anderson RJ, McCartney R, et al. Renal tubular acidosis associated with toluene "sniffing". N Engl J Med 1974; 290:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VIGLIANI EC, SAITA G. BENZENE AND LEUKEMIA. N Engl J Med 1964; 271:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosner F, Grünwald HW. Cytotoxic drugs and leukaemogenesis. Clin Haematol 1980; 9:663.
          </a>
         </li>
         <li class="breakAll">
          Shih RD. Hydrocarbons. In: Toxicological Emergencies, Goldfrank LR, Flomenbaum NE, Lewin NA, et al (Eds), Appleton and Lange, Stamford 1998. p.1384.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sturmann K, Mofenson H, Caraccio T. Methylene chloride inhalation: an unusual form of drug abuse. Ann Emerg Med 1985; 14:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Glue-sniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol 1991; 1:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones HE, Balster RL. Inhalant abuse in pregnancy. Obstet Gynecol Clin North Am 1998; 25:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold GL, Kirby RS, Langendoerfer S, Wilkins-Haug L. Toluene embryopathy: clinical delineation and developmental follow-up. Pediatrics 1994; 93:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khattak S, K-Moghtader G, McMartin K, et al. Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study. JAMA 1999; 281:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boynukalin FK, Baykal C. Prenatal diagnosis of multiple fetal anomalies in naphthalene-addicted pregnant women: a case report. Clin Exp Obstet Gynecol 2014; 41:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hersh JH. Toluene embryopathy: two new cases. J Med Genet 1989; 26:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenenbein M, Casiro OG, Seshia MM, Debooy VD. Neonatal withdrawal from maternal volatile substance abuse. Arch Dis Child Fetal Neonatal Ed 1996; 74:F204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broussard LA, Brustowicz T, Pittman T, et al. Two traffic fatalities related to the use of difluoroethane. J Forensic Sci 1997; 42:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowen SE, Daniel J, Balster RL. Deaths associated with inhalant abuse in Virginia from 1987 to 1996. Drug Alcohol Depend 1999; 53:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Layzer RB, Fishman RA, Schafer JA. Neuropathy following abuse of nitrous oxide. Neurology 1978; 28:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vishnubhakat SM, Beresford HR. Reversible myeloneuropathy of nitrous oxide abuse: serial electrophysiological studies. Muscle Nerve 1991; 14:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartner M, Sinnott M, Silburn P. Paralysis caused by "nagging". Med J Aust 2007; 187:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwata K, O'Keefe GB, Karanas A. Neurologic problems associated with chronic nitrous oxide abuse in a non-healthcare worker. Am J Med Sci 2001; 322:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sethi NK, Mullin P, Torgovnick J, Capasso G. Nitrous oxide "whippit" abuse presenting with cobalamin responsive psychosis. J Med Toxicol 2006; 2:71.
          </a>
         </li>
         <li class="breakAll">
          Kaufman B, Sutin KM, Wahlander S, Miller SM. Anesthetics and neuromuscular blocking agents. In: Goldfrank's Toxicologic Emergencies, 6th, Goldfrank CR, Flomenbaum NE, Lewin NA, et al (Eds), Appleton &amp; Lange, Stamford 1998. p.873.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Largeau B, Karam A, Potey C, et al. Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels. Eur J Neurol 2022; 29:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mair D, Paris A, Zaloum SA, et al. Nitrous oxide-induced myeloneuropathy: a case series. J Neurol Neurosurg Psychiatry 2023; 94:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garakani A, Jaffe RJ, Savla D, et al. Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature. Am J Addict 2016; 25:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu M, Qiao Y, Li W, et al. Analysis of clinical characteristics and prognostic factors in 110 patients with nitrous oxide abuse. Brain Behav 2022; 12:e2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amos RJ, Amess JA, Hinds CJ, Mollin DL. Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care. Lancet 1982; 2:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 2006; 5:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oussalah A, Julien M, Levy J, et al. Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajaj D, Agrawal A, Gupta S, Bajaj S. Recreational Nitrous Oxide Abuse Causing Ischemic Stroke in a Young Patient: A Rare Case Report. Cureus 2018; 10:e3761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu M, Zhang J, Bu B. Isolated cortical vein thrombosis after nitrous oxide use in a young woman: a case report. BMC Neurol 2020; 20:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farhat W, Pariente A, Mijahed R. Extensive Cerebral Venous Thrombosis Secondary to Recreational Nitrous Oxide Abuse. Cerebrovasc Dis 2022; 51:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pratt DN, Patterson KC, Quin K. Venous thrombosis after nitrous oxide abuse, a case report. J Thromb Thrombolysis 2020; 49:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Indraratna P, Alexopoulos C, Celermajer D, Alford K. Acute ST-Elevation Myocardial Infarction, a Unique Complication of Recreational Nitrous Oxide Use. Heart Lung Circ 2017; 26:e41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oomens T, Riezebos RK, Amoroso G, Kuipers RS. Case report of an acute myocardial infarction after high-dose recreational nitrous oxide use: a consequence of hyperhomocysteinaemia? Eur Heart J Case Rep 2021; 5:ytaa557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faguer S, Ruiz J, Mari A. Massive hyperhomocysteinaemia as a complication of nitrous oxide inhalation. Br J Clin Pharmacol 2016; 81:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun W, Liao JP, Hu Y, et al. Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: A case report. World J Clin Cases 2019; 7:4057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhardwaj Shah A, Naidu SB. Pulmonary embolus associated with a rare provoking factor: recreational nitrous oxide use. BMJ Case Rep 2022; 15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caris MG, Kuipers RS, Kiestra BE, et al. Nitrous oxide abuse leading to extreme homocysteine levels and thrombosis in young adults: a case series. J Thromb Haemost 2023; 21:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wrońska-Nofer T, Palus J, Krajewski W, et al. DNA damage induced by nitrous oxide: study in medical personnel of operating rooms. Mutat Res 2009; 666:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbaz L, Mispelaere D, Boutemy M, Jounieaux V. [Pneumothorax following recreational inhalation of nitrous oxide]. Rev Mal Respir 2007; 24:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haverkos HW, Kopstein AN, Wilson H, Drotman P. Nitrite inhalants: history, epidemiology, and possible links to AIDS. Environ Health Perspect 1994; 102:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haverkos HW, Dougherty J. Health hazards of nitrite inhalants. Am J Med 1988; 84:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lange WR, Fralich J. Nitrite inhalants: promising and discouraging news. Br J Addict 1989; 84:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogart L, Bonsignore J, Carvalho A. Massive hemolysis following inhalation of volatile nitrites. Am J Hematol 1986; 22:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coleman MD, Coleman NA. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf 1996; 14:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradberry SM, Whittington RM, Parry DA, Vale JA. Fatal methemoglobinemia due to inhalation of isobutyl nitrite. J Toxicol Clin Toxicol 1994; 32:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Halleux C, Juurlink DN. Diagnosis and management of toxicity associated with the recreational use of nitrous oxide. CMAJ 2023; 195:E1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitz ZP, Hoffman RS. Magnetic resonance imaging in a patient with nitrous oxide-induced subacute combined degeneration of the spinal cord. Clin Toxicol (Phila) 2023; 61:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsden P, Sharma AA, Rotella JA. Review article: Clinical manifestations and outcomes of chronic nitrous oxide misuse: A systematic review. Emerg Med Australas 2022; 34:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards KE, Wenstone R. Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation. Br J Anaesth 2000; 84:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortiz F, de La Chapelle A, Bauer F, et al. Esmolol in the treatment of severe arrhythmia after acute trichloroethylene poisoning. Intensive Care Med 2000; 26:256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gindre G, Le Gall S, Condat P, Bazin JE. [Late ventricular fibrillation after trichloroethylene poisoning]. Ann Fr Anesth Reanim 1997; 16:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cámara-Lemarroy CR, Gónzalez-Moreno EI, Rodriguez-Gutierrez R, González-González JG. Clinical presentation and management in acute toluene intoxication: a case series. Inhal Toxicol 2012; 24:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Westhuyzen J, Fernandes-Costa F, Metz J. Cobalamin inactivation by nitrous oxide produces severe neurological impairment in fruit bats : protection by methionine and aggravation by folates. Life Sci 1982; 31:2001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiew AL, Raubenheimer JE, Berling I, et al. Just 'nanging' around - harmful nitrous oxide use: a retrospective case series and review of Internet searches, social media posts and the coroner's database. Intern Med J 2022; 52:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacy CB, Di Rocco A, Gould RJ. Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy. J Neurol 1992; 239:401.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6502 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22673000" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Youth risk behavior surveillance - United States, 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22673000" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Youth risk behavior surveillance - United States, 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22673000" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Youth risk behavior surveillance - United States, 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9701138" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The epidemiology of adolescent inhalant drug involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9701138" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The epidemiology of adolescent inhalant drug involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37358036" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Inhalant misuse reported to America's Poison Centers, 2001-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37358036" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Inhalant misuse reported to America's Poison Centers, 2001-2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1420537" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comparison of drug use rates for reservation Indian, non-reservation Indian and Anglo youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19340679" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends in volatile substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20403928" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Inhalant abuse: monitoring trends by using poison control data, 1993-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20403928" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Inhalant abuse: monitoring trends by using poison control data, 1993-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19085827" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The changing patterns of drug use among American Indian students over the past 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19085827" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The changing patterns of drug use among American Indian students over the past 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22882771" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Twenty-five years of volatile substance abuse mortality: a national mortality surveillance programme.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678512" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Increasing recreational nitrous oxide use: Should we worry? A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678512" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Increasing recreational nitrous oxide use: Should we worry? A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678512" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Increasing recreational nitrous oxide use: Should we worry? A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678512" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Increasing recreational nitrous oxide use: Should we worry? A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35678512" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Increasing recreational nitrous oxide use: Should we worry? A narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665100" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Inhalant use among urban American Indian youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15322411" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17433572" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Inhalant use and suicidality among incarcerated youth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8745138" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Inhalants to heroin: a prospective analysis from adolescence to adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3550655" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The abuse of volatile substances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11226839" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Inhalant abuse by adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2503175" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Neuropsychological consequences of volatile substance abuse: a population based study of secondary school pupils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2700603" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Mechanism of action of ethanol: initial central nervous system actions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9546794" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18813051" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Biologic effects of nitrous oxide: a mechanistic and toxicologic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16113204" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Butane encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16113204" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Butane encephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7950851" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Abuse of inhalants: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18813045" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Effect of nitrous oxide anesthesia on plasma homocysteine and endothelial function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15011232" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nitrous oxide "whippit" abuse presenting as clinical B12 deficiency and ataxia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8775919" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Inhalant abuse in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7617321" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Identifying the manifestations of inhalant abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8377742" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Other agents. Phencyclidine, marijuana, hallucinogens, inhalants, and anticholinergics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8377742" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Other agents. Phencyclidine, marijuana, hallucinogens, inhalants, and anticholinergics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5467774" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sudden sniffing death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10940962" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lead poisoning in a historical perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9543396" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Facial injury and airway threat from inhalant abuse: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1891741" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Severe frostbite caused by Freon gas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9615984" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Acute Halon (bromochlorodifluoromethane) toxicity by accidental and recreational inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9615984" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Acute Halon (bromochlorodifluoromethane) toxicity by accidental and recreational inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10326934" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Role of the primary care physician in problems of substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2550357" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Chronic neurological toxicity associated with exposure to volatile substances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24911841" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hydrocarbon toxicity: A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2777268" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Mechanism of sudden death associated with volatile substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18456329" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6613519" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cerebellar, cortical and functional impairment in toluene abusers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3247003" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Central nervous system effects of chronic toluene abuse--clinical, brainstem evoked response and magnetic resonance imaging studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2314597" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : White matter dementia in chronic toluene abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11496854" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Toxic leukoencephalopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11039461" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Brain SPECT findings in long-term inhalant abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3907347" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Gasoline sniffing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6254778" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Peripheral neuropathy due to gasoline sniffing - A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6682500" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Acute myopathy associated with gasoline sniffing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9798746" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Neurological and cognitive abnormalities associated with chronic petrol sniffing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9154447" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Leaded gasoline abuse: the role of tetraethyl lead.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23490054" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A prospective study of neurocognitive changes 15 years after chronic inhalant abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9127421" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Myocardial infarction after toluene inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18236220" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Glue (toluene) abuse: increased QT dispersion and relation with unexplained syncope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7667552" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Sudden cardiac death and substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/953880" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Letter: Sudden sniffing death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12507056" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Toxicologic myocardial sensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16919292" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A possible mechanism of halocarbon-induced cardiac sensitization arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8455004" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Fatality due to recreational use of chlorodifluoromethane and chloropentafluoroethane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10414425" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Reactive airways dysfunction syndrome following exposure to a fluorocarbon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2777269" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Chronic non-neurological toxicity from volatile substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18528314" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Youth risk behavior surveillance--United States, 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7235417" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Syndromes of toluene sniffing in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4815223" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Renal tubular acidosis associated with toluene "sniffing".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14185112" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : BENZENE AND LEUKEMIA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6778643" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cytotoxic drugs and leukaemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6778643" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cytotoxic drugs and leukaemogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4025992" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Methylene chloride inhalation: an unusual form of drug abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1912400" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Glue-sniffing and distal renal tubular acidosis: sticking to the facts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9547765" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Inhalant abuse in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7510062" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Toluene embryopathy: clinical delineation and developmental follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10188661" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pregnancy outcome following gestational exposure to organic solvents: a prospective controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24779257" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Prenatal diagnosis of multiple fetal anomalies in naphthalene-addicted pregnant women: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2471833" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Toluene embryopathy: two new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8777686" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Neonatal withdrawal from maternal volatile substance abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9397568" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Two traffic fatalities related to the use of difluoroethane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080050" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Deaths associated with inhalant abuse in Virginia from 1987 to 1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/205816" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Neuropathy following abuse of nitrous oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1992294" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Reversible myeloneuropathy of nitrous oxide abuse: serial electrophysiological studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17874987" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Paralysis caused by "nagging".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11570786" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Neurologic problems associated with chronic nitrous oxide abuse in a non-healthcare worker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18072118" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Nitrous oxide "whippit" abuse presenting with cobalamin responsive psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18072118" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Nitrous oxide "whippit" abuse presenting with cobalamin responsive psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35460312" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Myeloneuropathy induced by recreational nitrous oxide use with variable exposure levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37253616" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Nitrous oxide-induced myeloneuropathy: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037733" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35307992" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Analysis of clinical characteristics and prognostic factors in 110 patients with nitrous oxide abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6126709" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17052662" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Vitamin B12, folic acid, and the nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31018613" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Global Burden Related to Nitrous Oxide Exposure in Medical and Recreational Settings: A Systematic Review and Individual Patient Data Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30820381" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Recreational Nitrous Oxide Abuse Causing Ischemic Stroke in a Young Patient: A Rare Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33081755" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Isolated cortical vein thrombosis after nitrous oxide use in a young woman: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34515072" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Extensive Cerebral Venous Thrombosis Secondary to Recreational Nitrous Oxide Abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31820264" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Venous thrombosis after nitrous oxide abuse, a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291664" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Acute ST-Elevation Myocardial Infarction, a Unique Complication of Recreational Nitrous Oxide Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33598625" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Case report of an acute myocardial infarction after high-dose recreational nitrous oxide use: a consequence of hyperhomocysteinaemia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26521848" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Massive hyperhomocysteinaemia as a complication of nitrous oxide inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31832409" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35288427" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Pulmonary embolus associated with a rare provoking factor: recreational nitrous oxide use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36700505" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Nitrous oxide abuse leading to extreme homocysteine levels and thrombosis in young adults: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19439331" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : DNA damage induced by nitrous oxide: study in medical personnel of operating rooms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17519814" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : [Pneumothorax following recreational inhalation of nitrous oxide].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9644194" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Nitrite inhalants: history, epidemiology, and possible links to AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2894765" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Health hazards of nitrite inhalants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2720177" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Nitrite inhalants: promising and discouraging news.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3717148" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Massive hemolysis following inhalation of volatile nitrites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8828017" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Drug-induced methaemoglobinaemia. Treatment issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8145358" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Fatal methemoglobinemia due to inhalation of isobutyl nitrite.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37604519" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Diagnosis and management of toxicity associated with the recreational use of nitrous oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38060330" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Magnetic resonance imaging in a patient with nitrous oxide-induced subacute combined degeneration of the spinal cord.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35695047" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Review article: Clinical manifestations and outcomes of chronic nitrous oxide misuse: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10895761" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Successful resuscitation from recurrent ventricular fibrillation secondary to butane inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10784325" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Esmolol in the treatment of severe arrhythmia after acute trichloroethylene poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9686084" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : [Late ventricular fibrillation after trichloroethylene poisoning].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22642292" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Clinical presentation and management in acute toluene intoxication: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7176808" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Cobalamin inactivation by nitrous oxide produces severe neurological impairment in fruit bats : protection by methionine and aggravation by folates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34029427" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Just 'nanging' around - harmful nitrous oxide use: a retrospective case series and review of Internet searches, social media posts and the coroner's database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1403023" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
